Senior Director, Value, Evidence & Development Strategy

Beam Therapeutics•Cambridge, MA

13d•$260,000 - $320,000

About The Position

Beam is seeking a dynamic, visionary, and strategic Senior Director, Value, Evidence, & Development Strategy to spearhead the global HEOR strategy for our sickle cell disease program (risto-cel) and other pipeline programs as they emerge . In this high-impact role, the Senior Director, Value, Evidence, & Development Strategy will develop and execute evidence-generation plans, manage stakeholder relationships, and shape external communication strategies. You will partner closely with Clinical Development, Medical Communications and Scientific Publications, Value and Evidence Strategy, Commercial, R&D, and additional cross-functional teams. If you thrive in a collaborative, mission-driven environment and are eager to shape the future of sickle cell disease care, we want you to bring your expertise and passion to Beam.

Requirements

Master’s Degree or higher in Health Economics and Outcomes Research or a relevant discipline.
Formal training in Epidemiology/Health Services Research required.
At least 10+ years’ experience in observational research study management AND data analytics, either within industry or with an observational research consulting firm.
Demonstrated ability to lead in a matrixed, cross-functional environment, combining strategic agility with strong business acumen.
Independent, proactive operator with strong ownership.
Cross functional collaboration with Clinical, Regulatory, Commercial, Medical Operations, and Publications while maintaining medical/scientific integrity.
Excellent communication, collaboration, and problem-solving skills.

Nice To Haves

Proven track record in drug development, with rare disease experience and an existing network of hematologists preferred.

Responsibilities

Provide strategic input to disease prioritization, target product profiles, clinical trial protocols, clinical development plans, and regulatory submissions; lead development of clinical sections for Investigator’s Brochures, briefing books, safety updates, IND/NDA materials, and responses to Health Authority questions.
Develop, validate, and integrate patient‑centered outcomes (PROs) into protocols and analyses.
Interpret clinical trial results (including PROs and healthcare resource use) and partner with Clinical Development/Biostatistics on Statistical Analysis Plans (SAPs) and post‑hoc analyses.
Lead a fit‑for‑purpose RWE strategy (EHR, claims, registries, hybrid/open datasets) including natural history/registry design and governance to inform endpoints, recruitment, and post‑authorization effectiveness/safety assessments.
Develop and operationalize external/synthetic control arm approaches (e.g., matched registry cohorts, Bayesian borrowing) for single‑arm or small‑population studies typical in cell & gene therapy.
Provide operational oversight of Medical Affairs evidence generation, including vendor/CRO governance, milestone/deliverable tracking, data‑quality plans, risk management, and on‑time execution across Medical Affairs–led studies; contribute to long‑term capability building (digital health, real‑world studies).
Elicit and integrate perspectives from patients, KOLs, policy leaders, and internal stakeholders (market access, marketing, patient advocacy) to ensure plans meet the needs of patients, HCPs, and payers.
Support Market Access on internal and external payer/policy initiatives (pricing and reimbursement, unmet medical need, regional market dynamics, evidence gaps) across the portfolio.
Support business decisions around ex-US strategy including, but not limited to, scoping ex-US opportunities, prioritizing country engagement, early scientific advice / parallel consultations with EMA and HTA bodies (e.g., HTACG/JSC), providing advice to development programs on endpoint selection to support product and reimbursement approvals ex-US, etc.
Anticipate payer evidence needs and budget‑impact critiques (including preparation for ICER Reviews).
Build and maintain economic models (cost‑effectiveness, budget impact) tailored to one‑time CGTs, addressing uncertainty/durability and caregiver burden.
Collaborate with Market Access to design innovative payment models and outcomes‑based agreements with pragmatic outcomes and tracking.
Lead the AMCP dossier and pre‑approval information exchange (PIE) strategy (6–12 months pre‑launch).
Work collaboratively with internal teams, consultants, and CROs to advance development of the portfolio.